UNSPSC 51111647: Nolatrexed

This classification denotes a thymidylate synthase inhibitor and folate antagonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier K75ZUN743Q. European Medicines Agency schedules Nolatrexed in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09342MIG. Nolatrexed generally arises in the molecular formula C14H12N4OS.

The term NOLATREXED is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 12 no. 2 1999, list 40.) NOLATREXED is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule nolatrexed under HS 29335995 and SITC 51576. As of Q4 2014, NOLATREXED remains the US FDA Preferred Term for this commodity. SMILES: S(C1C2C([NH]C(NC2=O)N)CCC1C)C1CCNCC1.

UNSPSC 51111647 Nolatrexed, a Commodity code, covers pharmaceutical products state and local government agencies purchase for health benefit programs and pharmacy operations. The Texas Health and Human Services Commission issued Request for Information RFI No. HHS0017013 in April 2026 to explore vendor capabilities for direct-to-manufacturer prescription fulfillment under a Therapeutic Pharmacy Initiative, indicating that state procurement under this code focuses on establishing alternative distribution channels and pricing models outside traditional pharmacy benefit manager and group purchasing organization structures. The RFI solicited vendor experience with direct contracting for self-insured employer and government health plans, negotiated net pricing without rebates, and value-based or outcomes-based agreement implementation. The solicitation reflects state interest in cost management and supply-chain efficiency for prescription medications.

The recent activity shows limited geographic representation in the available data, with the Texas Health and Human Services Commission as the sole identified issuing body. The RFI posted April 3, 2026 was exploratory in nature, designed to gather market intelligence rather than to award a contract, with no formal evaluation criteria, site visits, or binding timelines specified. The state indicated its intent to use vendor responses to develop detailed procurement specifications and pricing models for a subsequent formal RFP, suggesting that formal competitive solicitations under this code may follow once the state completes its information-gathering phase. No award value, budget allocation, or set-aside designations were identified in the RFI materials.